Maxim raised the firm’s price target on Nephros (NEPH) to $6 from $4.50 and keeps a Buy rating on the shares. The company’s Q2 results saw revenue, gross margins, and earnings all above consensus estimates, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEPH: